PBIO - Pressure BioSciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.1500
-0.0900 (-4.02%)
At close: 3:25PM EDT
Stock chart is not supported by your current browser
Previous Close2.2400
Open2.2350
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.9100 - 2.2500
52 Week Range0.6000 - 4.0300
Volume9,847
Avg. Volume18,520
Market Cap5.159M
Beta (5Y Monthly)0.92
PE Ratio (TTM)N/A
EPS (TTM)-9.0750
Earnings DateMay 13, 2020 - May 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.57
  • Pressure BioSciences Nearing Complete Sellout on Pre-launch Offering of Game-Changing UST System for Processing CBD Oil Into Water-soluble Nanoemulsions
    PR Newswire

    Pressure BioSciences Nearing Complete Sellout on Pre-launch Offering of Game-Changing UST System for Processing CBD Oil Into Water-soluble Nanoemulsions

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer, Can B Corp (OTC: CANBD), for one of its proprietary BaroShear K45 Ultra Shear Technology™ ("UST™")-based systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the absorption efficiency of today's macro or microemulsions of CBD Oil.

  • Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory
    PR Newswire

    Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the official opening of its new Ultra Shear Technology™ ("UST™") Demonstration Laboratory (the "UST Demo Lab"). The UST Demo Lab is located in the Company's South Easton, Massachusetts facility.

  • Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.
    PR Newswire

    Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Zacks Small Cap Research ("Zacks SCR") has released an updated research report in its on-going coverage on the Company.

  • Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument
    PR Newswire

    Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company plans to release a benchtop, R&D; scale, Ultra Shear Technology™ ("UST™")-based BaroShear instrument to the market in the third quarter of 2020. The Company believes this new instrument will address a significant un-met need in product formulation and development laboratories in the cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water.

  • Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil
    PR Newswire

    Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer for six (6) proprietary Ultra Shear Technology™ ("UST™")-based nanoemulsification systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the bioavailability of today's macro or microemulsions of CBD Oil.

  • Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine
    Newsfile

    Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine

    Cannabis Brightline Article Highlights Potential of PBI's UST Platform to Play Significant Role in Multiple Billion Dollar Markets - Including CBD, Cosmetics, Nutraceuticals, Biopharmaceuticals, and Food/Beverage South Easton, Massachusetts--(Newsfile Corp. - January 17, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company's new ...

  • Number of Published Scientific Papers Citing the Advantages of Pressure BioSciences' PCT Platform Remained Strong in 2019
    Newsfile

    Number of Published Scientific Papers Citing the Advantages of Pressure BioSciences' PCT Platform Remained Strong in 2019

    For the Second Straight Year, Over 20 Journal Articles Highlight the Benefits of PBI's Patented PCT Platform in Such Critical Areas of Research as Cancer, Food Safety, and Proteomics South Easton, Massachusetts--(Newsfile Corp. - January 9, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in ...

  • Pressure BioSciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
    GlobeNewswire

    Pressure BioSciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Significant Revenue Growth Reported in Consumable Products (158%) and Scientific Services (87%);Company Continues to Gain Momentum in Its PCT, BaroFold, and UST Technology.

  • Pressure BioSciences, Inc. to Discuss Third Quarter 2019 Financial Results and Provide Business Update
    GlobeNewswire

    Pressure BioSciences, Inc. to Discuss Third Quarter 2019 Financial Results and Provide Business Update

    SOUTH EASTON, Mass., Dec. 18, 2019 -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a.

  • Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.
    GlobeNewswire

    Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.

    SOUTH EASTON, Mass., Oct. 04, 2019 -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly.

  • Zacks Small Cap Research

    PBIO: Pressure BioSciences - Initiating Coverage

    By Elizabeth Senko, CFA OTC:PBIO READ THE FULL PBIO RESEARCH REPORT OUTLOOK : Pressure BioSciences (OTC:PBIO) is at a tipping point. Demand grew modestly through its early years but is expected to accelerate starting in 2020. After a decade of marketing its original PCT sample preparation platform to academic opinion leaders and early research customers, the

  • Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting
    GlobeNewswire

    Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting

    SOUTH EASTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples.  This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.

  • ACCESSWIRE

    Pressure BioSciences Provides Corporate Update, Focus on CBD Market and Growth Drivers for 2019-2020 in New SNNLive Video Interview on StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / September 27, 2019 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Richard T. Schumacher, President and CEO of Pressure ...

  • Pressure BioSciences’ PCT Platform Featured in Multiple Presentations at Major International Science Conference
    GlobeNewswire

    Pressure BioSciences’ PCT Platform Featured in Multiple Presentations at Major International Science Conference

    International HUPO plays a pivotal role in defining and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand the full complement and roles of proteins in human health and disease.  The multiple PCT-related presentations included development of new methods and applications using PBI’s unique PCT platform to advance knowledge and understanding in areas such as cancer research, with particular focus on cancer biomarker discovery. Ms. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "We are delighted to note that the number of PCT-related presentations at important international meetings is now exploding, in response to our years of investment in building collaborations and supporting research and the publication of now over 150 peer-reviewed scientific articles.

  • Pressure BioSciences, Inc. Discusses Major Advancements Its PCT, BaroFold, and BaroShear K45 Platforms
    Newsfile

    Pressure BioSciences, Inc. Discusses Major Advancements Its PCT, BaroFold, and BaroShear K45 Platforms

    Phoenix, Arizona--(Newsfile Corp. - September 18, 2019) - The Stock Day Podcast recently welcomed Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) ("the Company"), to discuss PBIO on Stock Day with its host Mr. Everett Jolley. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry.Mr. Jolly began the interview by welcoming Mr. Schumacher back to the ...

  • Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer 
    GlobeNewswire

    Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer 

    Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team South.

  • Pressure BioSciences’ PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and for Potential Clinical Diagnostics
    GlobeNewswire

    Pressure BioSciences’ PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and for Potential Clinical Diagnostics

    SOUTH EASTON, MA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of  scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers.  The Chinese team from Westlake University (Hangzhou, China) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems.  The Australian Proteome of Human Cancer (“ProCan”) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.

  • InvestmentPitch Media Video Discusses Pressure BioSciences' Two Purchase Orders for its Revolutionary BaroShear(tm) K45 Processing System for CBD Nanoemulsion - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses Pressure BioSciences' Two Purchase Orders for its Revolutionary BaroShear(tm) K45 Processing System for CBD Nanoemulsion - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 27, 2019) - Pressure BioSciences, Inc. (OTCQB: PBIO) announced two additional purchase orders for its revolutionary BaroShear™ K45 processing system. Based on the company's proprietary Ultra Shear Technology™ (UST™) platform, the BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing CBD manufacturers today: the extremely poor solubility of CBD Oil in water. Cannot view this video? ...

  • Pressure BioSciences Announces Two More Purchase Orders for its Revolutionary BaroShear K45 Processing System for Manufacturing Water-Soluble CBD
    GlobeNewswire

    Pressure BioSciences Announces Two More Purchase Orders for its Revolutionary BaroShear K45 Processing System for Manufacturing Water-Soluble CBD

    SOUTH EASTON, MA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced it has received two additional purchase orders for its revolutionary BaroShear™ K45 processing system. This novel processing system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing the CBD industry today: the extremely poor solubility of CBD Oil in water.

  • ACCESSWIRE

    Pressure BioSciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

    Record Consumables Sales, Strong Growth in BaroFold & UST Services, and Launch of Revolutionary CBD Processing System Highlight the 2019 Second Quarter; Company Believes Total Revenue Will More than Double ...

  • Stock Day Media Shares Discovery of Revolutionary Technology that Can Make High Quality, Highly Stable, Water-Soluble Nanoemulsions of CBD Oil with Pressure and Shear (Physics), Not Chemicals
    Newsfile

    Stock Day Media Shares Discovery of Revolutionary Technology that Can Make High Quality, Highly Stable, Water-Soluble Nanoemulsions of CBD Oil with Pressure and Shear (Physics), Not Chemicals

    Phoenix, Arizona--(Newsfile Corp. - August 14, 2019) - Stock Day Media prides itself in discovering companies with highly talented staff, revolutionary technologies, and the experience to combine these two key assets to change an industry. We have been watching an intriguing company for several years now, and with the news they recently released, we believe they are truly a company that has the talent, technology, experience, patent protection, and know-how to change ...

  • ACCESSWIRE

    Pressure BioSciences, Inc. to Discuss Second Quarter 2019 Financial Results and Provide Business Update

    Conference Call Scheduled for Thursday, August 15 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / August 13, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that ...

  • ACCESSWIRE

    Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45

    SOUTH EASTON, MA / ACCESSWIRE / July 25, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the initial sale of its revolutionary BaroShear™ K45 processing system. This novel instrument system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform.

  • ACCESSWIRE

    Pressure BioSciences Announces Second Major Contract Utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services

    SOUTH EASTON, MA / ACCESSWIRE / July 24, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, high pressure-based instruments, platform technologies and related consumables for the worldwide life sciences industry, today announced it has signed a contract services agreement with a world-renown, multi-billion dollar biotherapeutics company to enhance the process manufacturing of one of their candidate protein drugs. The manufacturing of therapeutic proteins can be a complex and challenging process.

  • ACCESSWIRE

    Pressure BioSciences' PCT Platform Highlighted at International Conference in China

    SOUTH EASTON, MA / ACCESSWIRE / July 18, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced that its flagship Barocycler 2320EXTREME instrument was prominently featured at a three-day, internationally-attended scientific conference held at the elite Westlake University (“Westlake”) in Hangzhou, China. One of the primary conference organizers was Professor Tiannan Guo, MD., PhD, a well-known protein research scientist. In 2017, Professor Guo’s Westlake laboratory was named a PBI Center of Excellence.